Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 6, 2015, Pages F614-F626

  Kobayashi, Namiko ^a   Ueno, Toshiharu ^a   Ohashi, Kumi ^a   Yamashita, Hanako ^a   Takahashi, Yukina ^a   Sakamoto, Kazuo ^a   Manabe, Shun ^a   Hara, Satoshi ^a   Takashima, Yasutoshi ^a   Dan, Takashi ^b   Pastan, Ira ^c   Miyata, Toshio ^b   Kurihara, Hidetake ^d   Matsusaka, Taiji ^e   Reiser, Jochen ^f   Nagata, Michio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f RUSH MEDICAL COLLEGE   (United States)

Author keywords

Endocytosis; Integrin; Kidney; Pathology; Plasminogen activator inhibitor type 1; Podocyte

Indexed keywords

BETA1 INTEGRIN; HEPARIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; BETA INTEGRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CELL DAMAGE; CELL LOSS; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; ENDOCYTOSIS; GLOMERULOSCLEROSIS; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION; ANIMAL; C57BL MOUSE; CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY; RANDOMIZATION; THROMBOSIS;

ANIMALS; CELL LINE; ENDOCYTOSIS; HEPARIN; HUMANS; INTEGRIN BETA CHAINS; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCYTES; RANDOM ALLOCATION; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; THROMBOSIS; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84930900875     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00616.2014     Document Type: Article

References (46)

1. Aita K, Etoh M, Hamada Yokoyama C H, Takahashi A, Suzuki T, Hara M, Nagata M. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract 112: c65–c70, 2009.
2. Bergstein JM, Riley M, Bang NU. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 327: 755–759, 1992.
3. Bolte S, Cordelières FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224: 213–232, 2006.
4. Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest 99: 1390–1398, 1997.
5. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160: 781–791, 2003.
6. Czekay RP, Loskutoff DJ. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol 220: 655–663, 2009.
7. D’Agati VD. Podocyte injury in focal segmental glomerulosclerosis: lessons from animal models (a play in five acts). Kidney Int 73: 399–406, 2008.
8. D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med 365: 2398–2411, 2011.
9. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93: 631–640, 2005.
10. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17: 2999–3012, 2006.
11. Elzi DJ, Lai Y, Song M, Hakala K, Weintraub ST, Shiio Y. Plasminogen activator inhibitor 1-insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc Natl Acad Sci USA 109: 12052–12057, 2012.
12. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129–1136, 2008.
13. George M, Rainey MA, Naramura M, Foster KW, Holzapfel MS, Willoughby LL, Ying G, Goswami RM, Gurumurthy CB, Band V, Satchell SC, Band H. Renal thrombotic microangiopathy in mice with combined deletion of endocytic recycling regulators EHD3 and EHD4. PLos One 6: e17838, 2011.
14. Hamano K, Iwano M, Akai Y, Sato H, Kubo A, Nishitani Y, Uyama H, Yoshida Y, Miyazaki M, Shiiki H, Kohno S, Dohi K. Expression of glomerular plasminogen activator inhibitor type I in glomerulonephritis. Am J Kidney Dis 39: 695–705, 2002.
15. Hayashida T, Jones JC, Lee CK, Schnaper HW. Loss of β1-integrin enhances TGF-[1]1-induced collagen expression in epithelial cells via increased αvβ3-integrin and Rac1 activity. J Biol Chem 285: 30741–30751, 2010.
16. Hedberg A, Fismen S, Fenton KA, Fenton C, Osterud B, Mortensen ES, Rekvig OP. Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. Arthritis Rheum 63: 1065–1075, 2011.
17. Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, Kiyomoto H, Ishii N, Okada K, Matsuo O, Hou FF, Vaughan DE, van Ypersele de Strihou C, Miyata T. A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration. Arterioscler Thromb Vasc Biol 33: 935–942, 2013.
18. Izuhara Y, Takahashi S, Nangaku M, Takizawa S, Ishida H, Kurokawa K, van Ypersele de Strihou C, Hirayama N, Miyata T. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 28: 672–677, 2008.
19. Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C, Miyata T. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab 30: 904–912, 2010.
20. Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR, Tipping PG. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 14: 1487–1495, 2003.
21. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54: 687–697, 1998.
22. Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV. The podocyte’s response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol 304: F333–F347, 2013.
23. Kurihara H, Harita Y, Ichimura K, Hattori S, Sakai T. SIRP-α-CD47 system functions as an intercellular signal in the renal glomerulus. Am J Physiol Renal Physiol 299: F517–F527, 2010.
24. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3: 35–45, 2005.
25. Matsusaka T, Sandgren E, Shintani A, Kon V, Pastan I, Fogo AB, Ichikawa I. Podocyte injury damages other podocytes. Podocyte injury damages other podocytes. J Am Soc Nephrol 22: 1275–1285, 2011.
26. Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 16: 1013–1023, 2005.
27. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 42: 148–160, 1992.
28. Nagata M. Pathogenesis of glomerulosclerosis: role of epithelial interactions. Clin Exp Nephrol 4: 173–181, 2000.
29. Nakamura T, Tanaka N, Hoguma N, Kazama T, Kobayashi I, Yokota S. The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy. J Am Soc Nephrol 11: 2434–2444, 1996.
30. Pozzi A, Jarad G, Moeckel GW, Coffa S, Zhang X, Gewin L, Eremina V, Hudson BG, Borza DB, Harris RC, Holzman LB, Phillips CL, Fassler R, Quaggin SE, Miner JH, Zent R. b1 integrin expression by podocytes is required to maintain glomerular structural integrity. Dev Biol 316: 288–301, 2008.
31. Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 5: 102–115, 2007.
32. Sachs N, Sonnenberg A. Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol 9: 200–210, 2013.
33. Sakairi T, Abe Y, Jat PS, Kopp JB. Cell-cell contact regulates gene expression in CDK4-transformed mouse podocytes. Am J Physiol Renal Physiol 299: F802–F809, 2010.
34. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671–675, 2012.
35. Schneider DJ, Chen Y, Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost 100: 1037–1040, 2008.
36. Slater SC, Ramnath RD, Uttridge K, Saleem MA, Cahill PA, Mathieson PW, Welsh GI, Satchell SC. Chronic exposure to laminar shear stress induces Kruppel-like factor 2 in glomerular endothelial cells and modulates interactions with co-cultured podocytes. Int J Biochem Cell Biol 44: 1482–1490, 2012.
37. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23–36, 2010.
38. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR, Saito Y, Betsholtz C. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161: 799–805, 2002.
39. Ueno T, Kobayashi N, Nakayama M, Takashima Y, Ohse T, Pastan I, Pippin JW, Shankland SJ, Uesugi N, Matsusaka T, Nagata M. Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int 83: 1065–1075, 2013.
40. Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 152: 741–752, 2001.
41. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat Med 17: 55–63, 2008.
42. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952–960, 2011.
43. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16: 2941–2952, 2005.
44. Xu Y, Hagege J, Mougenot B, Sraer JD, Rønne E, Rondeau E. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int 50: 2011–2019, 1996.
45. Yoshida Y, Shiiki H, Iwano M, Uyama H, Hamano K, Nishino T, Dohi K. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron 88: 24–29, 2001.
46. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke 3rd GW, Mundel P. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369: 2416–2423, 2013.